Penn Medicine's 2021 Updates in Care of the Hematologic Malignancies Patient
Update on Patient Care Treatment Strategies in Leukemia
Penn Medicine's 2021 Updates in Care of the Hematologic Malignancies Patient
Penn Medicine Updates on Blood/Marrow Transplantation & Cellular Therapy for Anemia & Thrombocytopenia: Does TXA Decrease the Bleeding Rate? Can We Achieve TI With Roxadustat? How Do ASCT Patients Respond to Vaccinations?
FEATURING
Patricia A. Ford
- 126 views
- March 3, 2021
- 1
Penn Medicine's 2021 Updates in Care of the Hematologic Malignancies Patient
UPenn Expert Discussion on MDS, MPN & Leukemia: Transfusion-Dependent MDS Patients, Patients Treated With Hydroxyurea for MPN, AML Pts to Treat With Ven + HMAs, Oral HMAs, Maintenance Azacitidine
FEATURING
Keith Pratz,
Shannon McCurdy,
Daria V. Babushok,
Alexander Perl,
Selina Luger,
Sunil Saroha
- 17 views
- March 3, 2021
Penn Medicine's 2021 Updates in Care of the Hematologic Malignancies Patient
2021 Penn Medicine Update on FLT3i in R/R AML: Gilteritinib Mono and in Combination With Venetoclax, Newer Agents in Frontline Intensive Therapy and Post-transplant Maintenance
FEATURING
Alexander Perl
- 114 views
- March 2, 2021
Penn Medicine's 2021 Updates in Care of the Hematologic Malignancies Patient
Penn Update on MPNs: Does PTG-300 Eliminate the Need for Therapeutic Phlebotomy in PV? Is Imetelstat Active in R/R MF? What Is the Role of BETi as an "Add On" to Ruxolitinib in MF?
FEATURING
Daria V. Babushok
- 66 views
- March 2, 2021
Penn Medicine's 2021 Updates in Care of the Hematologic Malignancies Patient
Penn Updates on CML: Do Cancer-Related Mutational Events at Diagnosis Predict Inferior Outcomes? Is Ponatinib Effective & Safe? Is Asciminib More Beneficial vs. Bosutinib in CP-CML Treated With > TKIs?
FEATURING
Daria V. Babushok
- 194 views
- March 2, 2021
- 2
Penn Medicine's 2021 Updates in Care of the Hematologic Malignancies Patient
Penn Update on Novel Therapies for Higher Risk MDS: What Is the Role of Pevonedistat & Sabatolimab? Is Venetoclax an Option? Should We Consider Magrolimab? Is Enasidenib Effective in IDH2 MDS?
FEATURING
Shannon McCurdy
- 233 views
- March 2, 2021
- 2